Top

Published in:

01-01-2018 | Original Paper

Is the DLQI appropriate for medical decision-making in psoriasis patients?

Authors: Adrienn Katalin Poór, Valentin Brodszky, Márta Péntek, László Gulácsi, Gábor Ruzsa, Bernadett Hidvégi, Péter Holló, Sarolta Kárpáti, Miklós Sárdy, Fanni Rencz

Published in: Archives of Dermatological Research | Issue 1/2018

Abstract

Dermatology Life Quality Index (DLQI) is the most commonly applied measure of health-related quality of life (HRQoL) in psoriasis patients. It is among defining criteria of moderate-to-severe psoriasis and present in treatment guidelines. Our objective was to estimate preference-based HRQoL values (i.e., utilities) for hypothetical health states described by the 10 items of the DLQI in psoriasis patients. Moreover, we compare results to findings of a similar study previously conducted among the general public. A cross-sectional survey was carried out among 238 psoriasis patients. Seven hypothetical DLQI-defined health states with total scores of 6, 11, and 16 (3–3 and 1 states, respectively) were evaluated by time trade-off method. The difference in DLQI scores between hypothetical health states was set at 5 points, as it exceeds the minimal clinically important difference (MCID). Utility scores were found to be homogenous across the seven hypothetical health states (range of means for the 6-point states 0.85–0.91, range of means for the 11-point states 0.83–0.85, and mean of 0.84 for the 16-point state). Overall, mean utilities assessed by psoriasis patients were higher for all seven states compared with the general public (mean difference 0.16–0.28; p < 0.001). In 11 out of the 15 comparisons between health states with DLQI scores differing larger than the MCID, there was no statistically significant difference in utility. Thus, in clinical settings, patients with DLQI scores differing more than the MCID may have identical HRQoL. Improving the definition of moderate-to-severe disease and reconsideration of the DLQI in clinical assessment of psoriasis patients are suggested.

Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY, Piguet V (2017) A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. Br J Dermatol 176:577–593. https://doi.org/10.1111/bjd.14788 CrossRefPubMed

Arnesen T, Trommald M (2005) Are QALYs based on time trade-off comparable?—A systematic review of TTO methodologies. Health Econ 14:39–53. https://doi.org/10.1002/hec.895 CrossRefPubMed

Attema AE, Edelaar-Peeters Y, Versteegh MM, Stolk EA (2013) Time trade-off: one methodology, different methods. Eur J Health Econ 14 Suppl 1:S53-64. https://doi.org/10.1007/s10198-013-0508-x

Baron J, Asch DA, Fagerlin A, Jepson C, Loewenstein G, Riis J, Stineman MG, Ubel PA (2003) Effect of assessment method on the discrepancy between judgments of health disorders people have and do not have: a web study. Med Decis Making 23:422–434. https://doi.org/10.1177/0272989X03257277 CrossRefPubMed

Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY (2008) The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol 159:997–1035. https://doi.org/10.1111/j.1365-2133.2008.08832.x PubMed

Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY (2015) Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 230:27–33. https://doi.org/10.1159/000365390 CrossRefPubMed

Both H, Essink-Bot ML, Busschbach J, Nijsten T (2007) Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 127:2726–2739. https://doi.org/10.1038/sj.jid.5701142 CrossRefPubMed

Brooks R (1996) EuroQol: the current state of play. Health Policy 37:53–72. https://doi.org/10.1016/0168-8510(96)00822-6 CrossRefPubMed

Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, Sexton SA, McCall CO, Goldstein MK (2004) A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc 9:160–168. https://doi.org/10.1046/j.1087-0024.2003.09112.x CrossRefPubMed

10.

Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108. https://doi.org/10.1097/00005650-199711000-00002 CrossRefPubMed

11.

Dolan P (1999) Whose preferences count? Med Decis Making 19:482–486. https://doi.org/10.1177/0272989X9901900416 CrossRefPubMed

12.

Eissing L, Rustenbach SJ, Krensel M, Zander N, Spehr C, Radtke MA, Naldi L, Augustin M (2016) Psoriasis registries worldwide: systematic overview on registry publications. J Eur Acad Dermatol Venereol 30:1100–1106. https://doi.org/10.1111/jdv.13634 CrossRefPubMed

13.

EUnetHTA. Methods for health economic evaluations—a guideline based on current practices in Europe Final (2015) http://www.eunethta.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/Methods%20for%20health%20economic%20evaluations%20A%20guideline%20based%20on%20current%20practices%20in%20Europe_Guideline_Final%20May%202015.pdf. Accessed 11 July 2017

14.

European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis (2004) http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf. Accessed 22 July 2017

15.

EuroQol G (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208. https://doi.org/10.1016/0168-8510(90)90421-9 CrossRef

16.

Finlay AY (2005) Current severe psoriasis and the rule of tens. Br J Dermatol 152:861–867. https://doi.org/10.1111/j.1365-2133.2005.06502.x CrossRefPubMed

17.

Finlay AY (2014) Quality of life in dermatology: after 125 years, time for more rigorous reporting. Br J Dermatol 170:4–6. https://doi.org/10.1111/bjd.12737 CrossRefPubMed

18.

Finlay AY, Basra MK, Piguet V, Salek MS (2012) Dermatology life quality index (DLQI): a paradigm shift to patient-centered outcomes. J Invest Dermatol 132:2464–2465. https://doi.org/10.1038/jid.2012.147 CrossRefPubMed

19.

Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210–216. https://doi.org/10.1111/j.1365-2230.1994.tb01167.x CrossRefPubMed

20.

Fredriksson T, Pettersson U (1978) Severe psoriasis–oral therapy with a new retinoid. Dermatologica 157:238–244. https://doi.org/10.1159/000250839 CrossRefPubMed

21.

Gaulin C, Sebaratnam DF, Fernandez-Penas P (2015) Quality of life in non-melanoma skin cancer. Australas J Dermatol 56:70–76. https://doi.org/10.1111/ajd.12205 CrossRefPubMed

22.

Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M (2015) Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). J Eur Acad Dermatol Venereol 29:452–456. https://doi.org/10.1111/jdv.12576 CrossRefPubMed

23.

He Z, Lo Martire R, Lu C, Liu H, Ma L, Huang Y, Li Y, Sun L, Bai Y, Liu W, Zha X (2017) Rasch analysis of the Dermatology Life Quality Index reveals limited application to Chinese patients with skin disease. Acta Derm Venereol. https://doi.org/10.2340/00015555-2742

24.

Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY (2005) Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 125:659–664. https://doi.org/10.1111/j.0022-202X.2005.23621.x CrossRefPubMed

25.

Khanna D, Ahmed M, Furst DE, Ginsburg SS, Park GS, Hornung R, Tsevat J (2007) Health values of patients with systemic sclerosis. Arthritis Rheum 57:86–93. https://doi.org/10.1002/art.22465 CrossRefPubMed

26.

Khanna D, Frech T, Khanna PP, Kaplan RM, Eckman MH, Hays RD, Ginsburg SS, Leonard AC, Tsevat J (2010) Valuation of scleroderma and psoriatic arthritis health states by the general public. Health Qual Life Outcomes 8:112. https://doi.org/10.1186/1477-7525-8-112 CrossRefPubMedPubMedCentral

27.

Leeyaphan C, Wanitphakdeedecha R, Manuskiatti W, Kulthanan K (2011) Measuring melasma patients’ quality of life using willingness to pay and time trade-off methods in Thai population. BMC Dermatol 11:16. https://doi.org/10.1186/1471-5945-11-16 CrossRefPubMedPubMedCentral

28.

Liu Y, Li T, An J, Zeng W, Xiao S (2016) Rasch analysis holds no brief for the use of the Dermatology Life Quality Index (DLQI) in Chinese neurodermatitis patients. Health Qual Life Outcomes 14:17. https://doi.org/10.1186/s12955-016-0419-5 CrossRefPubMedPubMedCentral

29.

Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M (1999) Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 141:1067–1075. https://doi.org/10.1046/j.1365-2133.1999.03207.x CrossRefPubMed

30.

Marchesoni A, Altomare G, Matucci-Cerinic M, Balato N, Olivieri I, Salvarani C, Lotti T, Scarpa R, Vena GA, Valesini G, Giannetti A (2010) An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease. J Eur Acad Dermatol Venereol 24:578–586. https://doi.org/10.1111/j.1468-3083.2009.03474.x CrossRefPubMed

31.

Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P (2005) Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta Derm Venereol 85:409–413. https://doi.org/10.1080/00015550510032832 CrossRefPubMed

32.

Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303:1–10. https://doi.org/10.1007/s00403-010-1080-1 CrossRefPubMed

33.

Nijsten T (2012) Dermatology life quality index: time to move forward. J Invest Dermatol 132:11–13. https://doi.org/10.1038/jid.2011.354 CrossRefPubMed

34.

Nijsten T, Meads DM, de Korte J, Sampogna F, Gelfand JM, Ongenae K, Evers AW, Augustin M (2007) Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol 127:2315–2322. https://doi.org/10.1038/sj.jid.5700875 CrossRefPubMed

35.

Nijsten T, Meads DM, McKenna SP (2006) Dimensionality of the dermatology life quality index (DLQI): a commentary. Acta Derm Venereol 86:284–285. https://doi.org/10.2340/00015555-0075 author reply 285–286.CrossRefPubMed

36.

Ofenloch RF, Diepgen TL, Weisshaar E, Elsner P, Apfelbacher CJ (2014) Assessing health-related quality of life in hand eczema patients: how to overcome psychometric faults when using the dermatology life quality index. Acta Derm Venereol 94:658–662. https://doi.org/10.2340/00015555-1842 CrossRefPubMed

37.

Ogorevc M, Murovec N, Fernandez NB, Rupel VP (2017) Questioning the differences between general public vs. patient based preferences towards EQ-5D-5L defined hypothetical health states. Health Policy. https://doi.org/10.1016/j.healthpol.2017.03.011 PubMed

38.

Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Honigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B (2009) European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23 Suppl 2:1–70. https://doi.org/10.1111/j.1468-3083.2009.03389.x

39.

Poor AK, Rencz F, Brodszky V, Gulacsi L, Beretzky Z, Hidvegi B, Hollo P, Karpati S, Pentek M (2017) Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual Life Res. https://doi.org/10.1007/s11136-017-1699-x PubMed

40.

Puig L, Carrascosa JM, Carretero G, de la Cueva P, Lafuente-Urrez RF, Belinchon I, Sanchez-Regana M, Garcia-Bustinduy M, Ribera M, Alsina M, Ferrandiz C, Fonseca E, Garcia-Patos V, Herrera E, Lopez-Estebaranz JL, Marron SE, Moreno JC, Notario J, Rivera R, Rodriguez-Cerdeira C, Romero A, Ruiz-Villaverde R, Taberner R, Vidal D (2013) Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 104:694–709. https://doi.org/10.1016/j.adengl.2013.04.013 CrossRefPubMed

41.

Rencz F, Baji P, Gulacsi L, Karpati S, Pentek M, Poor AK, Brodszky V (2016) Discrepancies between the Dermatology Life Quality Index and utility scores. Qual Life Res 25:1687–1696. https://doi.org/10.1007/s11136-015-1208-z CrossRefPubMed

42.

Rencz F, Brodszky V, Stalmeier PF, Tamasi B, Karpati S, Pentek M, Baji P, Mitev AZ, Gulacsi L (2016) Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. Br J Dermatol 175:593–599. https://doi.org/10.1111/bjd.14647 CrossRefPubMed

43.

Rencz F, Kemeny L, Gajdacsi JZ, Owczarek W, Arenberger P, Tiplica GS, Stanimirovic A, Niewada M, Petrova G, Marinov LT, Kazandhieva J, Pentek M, Brodszky V, Gulacsi L (2015) Use of biologics for psoriasis in Central and Eastern European countries. J Eur Acad Dermatol Venereol 29:2222–2230. https://doi.org/10.1111/jdv.13222 CrossRefPubMed

44.

Rencz F, Poór AK, Péntek M, Holló P, Kárpáti S, Gulácsi L, Szegedi A, Remenyik É, Hidvégi B, Herszényi K, Jókai H, Beretzky Z, Brodszky V (2017) A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: potential biases in treatment decisions. J Eur Acad Dermatol Venereol. https:dx.doi.org/10.1111/jdv.14676

45.

Sampogna F, Puig L, Spuls P, Girolomoni G, Radtke MA, Kirby B, Brunori M, Bergmans P, Smirnov P, Rundle J, Lavie F, Paul C (2017) Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study. Br J Dermatol 176:1195–1203. https://doi.org/10.1111/bjd.15243 CrossRefPubMed

46.

Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W (2003) Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol 148:1153–1160. https://doi.org/10.1046/j.1365-2133.2003.05156.x CrossRefPubMed

47.

Schmitt J, Meurer M, Klon M, Frick KD (2008) Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 158:351–359. https://doi.org/10.1111/j.1365-2133.2007.08354.x CrossRefPubMed

48.

Seidler AM, Bayoumi AM, Goldstein MK, Cruz PD Jr, Chen SC (2012) Willingness to pay in dermatology: assessment of the burden of skin diseases. J Invest Dermatol 132:1785–1790. https://doi.org/10.1038/jid.2012.50 CrossRefPubMed

49.

Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD (2009) British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 161:987–1019. https://doi.org/10.1111/j.1365-2133.2009.09505.x CrossRefPubMed

50.

Stalmeier PF, Goldstein MK, Holmes AM, Lenert L, Miyamoto J, Stiggelbout AM, Torrance GW, Tsevat J (2001) What should be reported in a methods section on utility assessment? Med Decis Making 21:200–207. https://doi.org/10.1177/0272989x0102100305 CrossRefPubMed

51.

Stiggelbout AM, de Vogel-Voogt E (2008) Health state utilities: a framework for studying the gap between the imagined and the real. Value Health 11:76–87. https://doi.org/10.1111/j.1524-4733.2007.00216.x CrossRefPubMed

52.

Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5:1–30. https://doi.org/10.1016/0167-6296(86)90020-2 CrossRefPubMed

53.

Torrance GW (1987) Utility approach to measuring health-related quality of life. J Chronic Dis 40:593–603. https://doi.org/10.1016/0021-9681(87)90019-1 CrossRefPubMed

54.

Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP (2012) Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol 132:76–84. https://doi.org/10.1038/jid.2011.238 CrossRefPubMed

55.

Ubel PA, Loewenstein G, Jepson C (2003) Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 12:599–607. https://doi.org/10.1023/A:1025119931010 CrossRefPubMed

56.

Versteegh MM, Brouwer WB (2016) Patient and general public preferences for health states: a call to reconsider current guidelines. Soc Sci Med 165:66–74. https://doi.org/10.1016/j.socscimed.2016.07.043 CrossRefPubMed

57.

Wakkee M, Thio HB, Spuls PI, de Jong EM, Nijsten T (2008) Evaluation of the reimbursement criteria for biological therapies for psoriasis in the Netherlands. Br J Dermatol 158:1159–1161. https://doi.org/10.1111/j.1365-2133.2008.08512.x CrossRefPubMed

Title: Is the DLQI appropriate for medical decision-making in psoriasis patients?
Authors: Adrienn Katalin Poór
Valentin Brodszky
Márta Péntek
László Gulácsi
Gábor Ruzsa
Bernadett Hidvégi
Péter Holló
Sarolta Kárpáti
Miklós Sárdy
Fanni Rencz
Publication date: 01-01-2018
Publisher: Springer Berlin Heidelberg
Published in: Archives of Dermatological Research / Issue 1/2018
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-017-1794-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Is the DLQI appropriate for medical decision-making in psoriasis patients?

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Dermal–epidermal separation methods: research implications

Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case–control study

Mediterranean diet: fresh herbs and fresh vegetables decrease the risk of Androgenetic Alopecia in males

The role of dermoscopy in the diagnosis of distal lateral subungual onychomycosis

Quality assessment of atopic dermatitis clinical practice guidelines in ≤ 18 years

IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review